mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.
Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. · 2018
Read mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. by Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5991564.txt.
Introduction
Grady and co-authors test which tissue measures best track disease burden in m.3243A>G mitochondrial disease. Their study appeared in EMBO Molecular Medicine. This variant causes a common, varied neurogenetic disorder. Mutation load can be read in blood, urine, or muscle. The team modelled which reading links most tightly to burden. Blood samples numbered 231 and urine 235. Muscle samples numbered 77.
Mutation levels correlated across the three tissues, they report. Blood levels fall by about 2.3 percent per year. Age-corrected blood values were the handiest reliable measure. In muscle, copy number added more signal about burden. Urine values needed a sex adjustment formula.
Catalog record
| CREATOR | Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease By John P Grady, Sarah J Pickett, Yi Shiau Ng, Charlotte L Alston, Emma L Blakely, Steven A Hardy, Catherine L Feeney, Alexandra A Bright, Andrew M Schaefer, Gráinne S Gorman, Richard JQ McNally, Robert W Taylor Published in: EMBO Molecular Medicine DOI: 10.15252/emmm.201708262 ABSTRACT Abstract Mitochondrial disease associated with the pathogenic m.3243A>G variant is a common, clinically heterogeneous, neurogenetic disorder. Using multiple linear regression and linear mixed modelling, we evaluated which commonly assayed tissue (blood N = 231, urine N = 235, skeletal muscle N = 77) represents the m.3243A>G mutation load and mitochondrial DNA (mtDNA) copy number most strongly associated with disease burden and progression. m.3243A>G levels are correlated in blood, muscle and urine (R 2 = 0.61–0.73). Blood heteroplasmy declines by ~2.3%/year; we have extended previously published methodology to adjust for age. In urine, males have higher mtDNA copy number and ~20% higher m.3243A>G mutation load; we present formulas to adjust for this. Blood is the most highly correlated mutation measure for disease burden and progression in m.3243A>G‐harbouring individuals; increasing age and heteroplasmy contribute (R 2 = 0.27, P < 0.001). In muscle, heteroplasmy, age and mtDNA copy number explain a higher proportion of variability in disease burden (R 2 = 0.40, P < 0.001), although activity level and disease severity are likely to affect copy number. Whilst our data indicate that age‐corrected blood m.3243A>G heteroplasmy is the most convenient and reliable measure for routine clinical assessment, additional factors such as mtDNA copy number may also influence disease severity. Keywords: m.3243A>G, MELAS, mitochondrial disease, mtDNA copy number, mtDNA heteroplasmy Subject Categories: Genetics, Gene Therapy & Genetic Disease INTRODUCTION The pathogenic mitochondrial DNA (mtDNA) m.3243A>G variant in the MT‐TL1 gene (encoding mt‐tRNALeu(UUR)) is the most common heteroplasmic mtDNA disease genotype (Goto et al, 1990; Elliott et al, 2008; Gorman et al, 2015, 2016). Disease burden and progression vary greatly between individuals, and the associated clinical spectrum is broad (Nesbitt et al, 2013). The cause of this heterogeneity is poorly understood; consequently, disease burden and long‐term prognosis are very difficult to predict (Chinnery et al, 1997; Kaufmann et al, 2011; Mancuso et al, 2014; Weiduschat et al, 2014; Fayssoil et al, 2017). In individuals harbouring m.3243A>G, mutant and wild‐type mtDNA molecules coexist within the same cell, a situation termed heteroplasmy. Tissue segregation patterns of m.3243A>G vary widely; post‐mitotic tissues such as muscle have higher levels of mutant mtDNA, whilst levels in blood decrease significantly over time (Sue et al, 1998; Rahman et al, 2001; Pyle et al, 2007; Rajasimha et al, 2008; Mehrazin et al, 2009; de Laat et al, 2012). Although patients with very severe disease tend to have a high proportion of mutant mtDNA, the relationship between heteroplasmy level and clinical phenotype is not straightforward and such intra‐individual variation between tissues adds to the uncertainty (Chinnery et al, 1997; Fayssoil et al, 2017). We aimed to determine which putative prognostic factors are most associated with m.3243A>G‐related mitochondrial disease burden and progression. To answer this question, we characterised the levels of heteroplasmy and mtDNA copy number in three commonly sampled tissues: blood, urine and skeletal muscle, in 242 m.3243A>G carriers (including 195 symptomatic patients) from the MRC Mitochondrial Disease Patient Cohort UK. Using multiple linear regression, we ascertained which m.3243A>G heteroplasmy measure and mtDNA copy number were the most associated with total disease burden, as determined by the Newcastle Mitochondrial Disease Adult Scale (NMDAS) (Schaefer et al, 2006). We used linear mixed modelling to investigate disease progression. RESULTS m.3243A>G heteroplasmy measures in all three tissues are correlated In the first instance, we sought to characterise the three measurements of heteroplasmy; all are significantly correlated. The strongest relationship is between blood and urine heteroplasmy levels (Fig 1A; R 2 = 0.73, P < 0.001; interaction with age included for a linear fit, P < 0.001), followed by muscle and blood heteroplasmy levels (Fig 1B; R 2 = 0.64, P < 0.001, interaction with age included, P = 0.029). Finally, urine and muscle levels are correlated (Fig 1C; R 2 = 0.61, P < 0.001, sex term included, see below). Urine levels are significantly lower than muscle (slope = 0.75, 95% CI = 0.60–0.91, P < 0.001). [Figure: Correlations between heteroplasmy measurements and their relationship with age Urine and blood heteroplasmy correlation (N = 224, R 2 = 0.73, P < 0.001; interaction with age included, P < 0.001)Muscle and blood heteroplasmy correlation (N = 74, R 2 = 0.64, P < 0.001; interaction with age included, P = 0.029).Muscle and urine heteroplasmy correlation, showing different intercepts for males and females (N = 75, R 2 = 0.61, P < 0.001).The relationship between age and muscle heteroplasmy levels (N = 77, R 2 = 0.0, P = 0.491).The relationship between age and blood heteroplasmy levels (N = 231, R 2 = 0.32, slope = −0.56, 95% CI = −0.67, −0.45, P < 0.001).The relationship between age and urine heteroplasmy levels (N = 235, R 2 = 0.22, slope = −0.42, 95% CI = −0.62, −0.22, P < 0.001).Data information: Points represent mean heteroplasmy level for each individual, and linear regression lines are shown with 95% confidence intervals.] Blood and urine m.3243A>G heteroplasmy levels are negatively correlated with age The correlation between muscle and blood heteroplasmy (Fig 1A) shows that younger individuals tend to have higher blood heteroplasmy levels, including age in the model increased R 2 from 0.38 to 0.64 (P < 0.001), consistent with previous reports of a decline in blood levels with age (Rahman et al, 2001; Pyle et al, 2007; Rajasimha et al, 2008). We therefore examined the relationship of all tissue heteroplasmy measures with age; both blood and urine heteroplasmy levels show significant negative correlations, although this is greater for blood than urine. Muscle heteroplasmy is not correlated with age (Fig 1D–F). Blood m.3243A>G heteroplasmy levels decline with time To evaluate reports of an exponential decline in blood m.3243A>G heteroplasmy level, we examined levels in all patients with multiple measurements (Fig 2). Blood levels have declined in the majority of patients observed for 4 years or more but this is not universal and some individuals appear to reach a terminal nonzero plateau of heteroplasmy; therefore, decline is not universally exponential. The rate of heteroplasmy change in blood is not associated with disease burden (P = 0.977), and individuals whose level increased or remained stationary had a similar disease burden to those whose levels decreased. [Figure: Decline of blood m.3243A>G heteroplasmy levelLongitudinal blood heteroplasmy levels in individuals with multiple measurements (N = 96). Each point represents one heteroplasmy measurement; points joined by a line representing individual patients. Patients observed over 4 years or more are highlighted in blue for those showing a decline (N = 21) or red for those who show no change or an increase (N = 14).] We regressed the rate of heteroplasmy change against initial mutation level, estimating a continuous decline of −0.0185/year (95% CI = −0.0421 to 0.0052), consistent with previous methodology (Rajasimha et al, 2008). However, the model is a poor fit to our data (R 2 = 0.06, P = 0.120); this is improved if age at